These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 15102080)

  • 1. Monitoring the 3-year efficacy of enzyme replacement therapy in fabry disease by repeated skin biopsies.
    Thurberg BL; Randolph Byers H; Granter SR; Phelps RG; Gordon RE; O'Callaghan M
    J Invest Dermatol; 2004 Apr; 122(4):900-8. PubMed ID: 15102080
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Globotriaosylceramide accumulation in the Fabry kidney is cleared from multiple cell types after enzyme replacement therapy.
    Thurberg BL; Rennke H; Colvin RB; Dikman S; Gordon RE; Collins AB; Desnick RJ; O'Callaghan M
    Kidney Int; 2002 Dec; 62(6):1933-46. PubMed ID: 12427118
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cardiac microvascular pathology in Fabry disease: evaluation of endomyocardial biopsies before and after enzyme replacement therapy.
    Thurberg BL; Fallon JT; Mitchell R; Aretz T; Gordon RE; O'Callaghan MW
    Circulation; 2009 May; 119(19):2561-7. PubMed ID: 19414635
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and efficacy of recombinant human alpha-galactosidase A replacement therapy in Fabry's disease.
    Eng CM; Guffon N; Wilcox WR; Germain DP; Lee P; Waldek S; Caplan L; Linthorst GE; Desnick RJ;
    N Engl J Med; 2001 Jul; 345(1):9-16. PubMed ID: 11439963
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term safety and efficacy of enzyme replacement therapy for Fabry disease.
    Wilcox WR; Banikazemi M; Guffon N; Waldek S; Lee P; Linthorst GE; Desnick RJ; Germain DP;
    Am J Hum Genet; 2004 Jul; 75(1):65-74. PubMed ID: 15154115
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sustained, long-term renal stabilization after 54 months of agalsidase beta therapy in patients with Fabry disease.
    Germain DP; Waldek S; Banikazemi M; Bushinsky DA; Charrow J; Desnick RJ; Lee P; Loew T; Vedder AC; Abichandani R; Wilcox WR; Guffon N
    J Am Soc Nephrol; 2007 May; 18(5):1547-57. PubMed ID: 17409312
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of a low dose, after a standard therapeutic dose, of agalsidase beta during enzyme replacement therapy in patients with Fabry disease.
    Lubanda JC; Anijalg E; Bzdúch V; Thurberg BL; Bénichou B; Tylki-Szymanska A
    Genet Med; 2009 Apr; 11(4):256-64. PubMed ID: 19265719
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase 1/2 clinical trial of enzyme replacement in fabry disease: pharmacokinetic, substrate clearance, and safety studies.
    Eng CM; Banikazemi M; Gordon RE; Goldman M; Phelps R; Kim L; Gass A; Winston J; Dikman S; Fallon JT; Brodie S; Stacy CB; Mehta D; Parsons R; Norton K; O'Callaghan M; Desnick RJ
    Am J Hum Genet; 2001 Mar; 68(3):711-22. PubMed ID: 11179018
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of enzyme replacement therapy on the cardiomyopathy of Anderson-Fabry disease: a randomised, double-blind, placebo-controlled clinical trial of agalsidase alfa.
    Hughes DA; Elliott PM; Shah J; Zuckerman J; Coghlan G; Brookes J; Mehta AB
    Heart; 2008 Feb; 94(2):153-8. PubMed ID: 17483124
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Low-dose agalsidase beta treatment in male pediatric patients with Fabry disease: A 5-year randomized controlled trial.
    Ramaswami U; Bichet DG; Clarke LA; Dostalova G; Fainboim A; Fellgiebel A; Forcelini CM; An Haack K; Hopkin RJ; Mauer M; Najafian B; Scott CR; Shankar SP; Thurberg BL; Tøndel C; Tylki-Szymanska A; Bénichou B; Wijburg FA
    Mol Genet Metab; 2019 May; 127(1):86-94. PubMed ID: 30987917
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and efficacy of enzyme replacement therapy with agalsidase beta: an international, open-label study in pediatric patients with Fabry disease.
    Wraith JE; Tylki-Szymanska A; Guffon N; Lien YH; Tsimaratos M; Vellodi A; Germain DP
    J Pediatr; 2008 Apr; 152(4):563-70, 570.e1. PubMed ID: 18346516
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A retrospective analysis of the potential impact of IgG antibodies to agalsidase beta on efficacy during enzyme replacement therapy for Fabry disease.
    Bénichou B; Goyal S; Sung C; Norfleet AM; O'Brien F
    Mol Genet Metab; 2009 Jan; 96(1):4-12. PubMed ID: 19022694
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterization of early disease status in treatment-naive male paediatric patients with Fabry disease enrolled in a randomized clinical trial.
    Wijburg FA; Bénichou B; Bichet DG; Clarke LA; Dostalova G; Fainboim A; Fellgiebel A; Forcelini C; An Haack K; Hopkin RJ; Mauer M; Najafian B; Scott CR; Shankar SP; Thurberg BL; Tøndel C; Tylki-Szymańska A; Ramaswami U
    PLoS One; 2015; 10(5):e0124987. PubMed ID: 25955246
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A detailed pathologic examination of heart tissue from three older patients with Anderson-Fabry disease on enzyme replacement therapy.
    Sheppard MN; Cane P; Florio R; Kavantzas N; Close L; Shah J; Lee P; Elliott P
    Cardiovasc Pathol; 2010; 19(5):293-301. PubMed ID: 19631563
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enzyme replacement therapy administered during hemodialysis in patients with Fabry disease.
    Kosch M; Koch HG; Oliveira JP; Soares C; Bianco F; Breuning F; Rasmussen AK; Schaefer RM
    Kidney Int; 2004 Sep; 66(3):1279-82. PubMed ID: 15327428
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enzyme replacement therapy in Japanese Fabry disease patients: the results of a phase 2 bridging study.
    Eto Y; Ohashi T; Utsunomiya Y; Fujiwara M; Mizuno A; Inui K; Sakai N; Kitagawa T; Suzuki Y; Mochizuki S; Kawakami M; Hosoya T; Owada M; Sakuraba H; Saito H
    J Inherit Metab Dis; 2005; 28(4):575-83. PubMed ID: 15902561
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cellular and tissue localization of globotriaosylceramide in Fabry disease.
    Askari H; Kaneski CR; Semino-Mora C; Desai P; Ang A; Kleiner DE; Perlee LT; Quezado M; Spollen LE; Wustman BA; Schiffmann R
    Virchows Arch; 2007 Oct; 451(4):823-34. PubMed ID: 17674039
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunofluorescence detection of globotriaosylceramide deposits in conjunctival biopsies of Fabry disease patients.
    Rozenfeld PA; Croxatto O; Ebner R; Fossati CA
    Clin Exp Ophthalmol; 2006; 34(7):689-94. PubMed ID: 16970764
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of recombinant alpha-galactosidase A therapy for amelioration of the cardiovascular manifestations of Fabry disease: an important role for endomyocardial biopsy.
    Buja LM
    Circulation; 2009 May; 119(19):2539-41. PubMed ID: 19451361
    [No Abstract]   [Full Text] [Related]  

  • 20. Clinical benefit of enzyme replacement therapy in Fabry disease.
    Breunig F; Weidemann F; Strotmann J; Knoll A; Wanner C
    Kidney Int; 2006 Apr; 69(7):1216-21. PubMed ID: 16609685
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.